A Phase 3 Randomized, Active-comparator-controlled Clinical Study to Evaluate the Efficacy and Safety of Ezetimibe/Atorvastatin Combination Tablet (MK-0653C) as Second Line Lipid Lowing Treatment in Chinese Participants
Phase of Trial: Phase III
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Atorvastatin/ezetimibe (Primary) ; Atorvastatin
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 20 Aug 2019 Planned End Date changed from 26 Mar 2021 to 26 Feb 2021.
- 20 Aug 2019 Planned primary completion date changed from 29 Jan 2021 to 1 Jan 2021.
- 30 May 2019 Status changed from not yet recruiting to recruiting.